ARCHIVES

Phase II Study of Veliparib Improves PFS by 35 Percent

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

Stimulus Bill Gives NIH A $10 Billion Boost Over Two Years, Puts Pressure On Institutes to Make Rapid Funding Decisions

February 13, 2009

Herceptin Recommended As Adjuvant For HER2 Positive Early Breast Cancer

May 27, 2005

Proton Beam Radiation Helps Cancer Patients Retain Vision

August 26, 2005

FDA Approves Taxotere For Node+ Breast Cancer

August 27, 2004

Three CBCCPs Say They’ll Appeal To NC On Termination

March 21, 1980

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

April 25, 2014